Welcure Drugs & Pharmaceuticals has submitted the undertaking for confirming the payment of interest/dividend/principal obligations for non-convertible securities under Regulation 57(5) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter and half year ended 30th September, 2023. Further, the compliance of the same is not applicable on the Company.
The above information is a part of company’s filings submitted to BSE.